Here, Josep-Maria Ribera, MD, PhD, of Germans Trias i Pujol University Hospital, Barcelona, Spain, discusses the potential of measurable residual…
Browsing: Acute Myelogenous Leukemia
Richard Stone, MD, of the Dana-Farber Cancer Institute, Boston, MA, talks about the latest advances that have been made in…
Antonio Almeida, MD, PhD, of the Instituto Português de Oncologia Francisco Gentil, Lisbon, Portugal, gives an overview of acute myeloid…
Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, of the University of Birmingham, Birmingham, UK, discusses the use of measurable residual…
Alan Burnett, MD, FRCP, of Cardiff University, Cardiff, UK, discusses the use of measurable residual disease (MRD) in acute myeloid…
Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, of the University of Birmingham, Birmingham, UK, discusses the use of targeted vs.…
Alan Burnett, MD, FRCP, of Cardiff University, Cardiff, UK, discusses the antibody-drug conjugate gemtuzumab ozogamicin for acute myeloid leukemia (AML).…
Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Charles Craddock,…
Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, of the University of Birmingham, Birmingham, UK, discusses how we can improve outcomes…
With the recent maturation of novel therapies for acute myeloid leukemia (AML), the field of AML therapeutics is rapidly progressing.…
Dr Fang Liu, of Chengdu Military General Hospital, Chengdu, Sichuan, P.R. China, discusses first-in-human CLL1-CD33 compound CAR T-cells as a…
There has been an influx of novel therapies within the field of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).…
The future of biology is becoming increasingly technologically-based. In this video, Dominique Bonnet, PhD, of the Francis Crick Institute, London,…
In this video, Dominique Bonnet, PhD, of the Francis Crick Institute, London, UK, outlines her group’s research into the biology…
Haematopoietic stem cells give rise to the multitude of blood cells in our circulatory system. In this video, Dominique Bonnet,…
At the 2018 European School of Haematology (ESH) Clinical Updates on Acute Leukaemias, held in Budapest, Hungary, Mark Levis, MD,…
New drugs for acute myeloid leukemia (AML) are constantly being developed. In this video, recorded at the 23rd Congress of…
There has been growing evidence that the combination of hypomethylating agents like azacitidine with immune checkpoint inhibitors could be a…
A large proportion of acute myeloid leukemia (AML) patients are treated by non-specialist community oncologists, who may not have the…
Epigenetic therapies are constantly developing in the field of acute myeloid leukemia (AML). In this video, recorded at the 23rd…
Acute myeloid leukemia (AML) has shown good responses to immunotherapies, including monoclonal antibodies, immune checkpoint inhibitors and bispecific antibodies. Here,…
Speaking from the 23rd Congress of the European Hematological Association (EHA) 2018 in Stockholm, Sweden, Naval Daver, MD, of the…
Andrew Wei, MBBS, PhD, of Monash University, Melbourne, Australia, presented results from the CAVEAT trial (ACTRN12616000445471) at the 23rd Congress…
Clinical trials have demonstrated the positive response rates for FLT3 inhibitors like quizartinib in relapsed FLT3-mutated acute myeloid leukemia (AML).…
Eunice Wang, MD, talks about the role for nivolumab maintenance in high-risk acute myeloid leukemia (AML) patients
Eunice Wang, MD, talks about some of the evolving treatment considerations for FLT3 mutated acute myeloid leukemia (AML) patients who…
Eunice Wang, MD, talks about what we’ve learned about gilteritinib in FLT3-ITD mutated acute myeloid leukemia (AML) patients at the…
The UK is in a leading position internationally for use of minimal residual disease (MRD) measurements in acute myeloid leukemia…
Richard Dillon, MBBS, from King’s College London, UK, discusses the current landscape for minimal residual disease (MRD) in acute myeloid…
Eunice Wang, MD, shares the potential impact of gilteritinib as maintenance therapy after allogenic hematopoietic stem cell transplantation in patients…
Eunice Wang, MD, talks about the impact of next-generation sequencing on treatment selection in acute myeloid leukemia (AML) at Annual…
Cancerous cells in acute myeloid leukemia (AML) utilize different metabolic pathways to normal cells. Using this difference in their biology,…
The treatment of acute myeloid leukemia (AML) patients who have relapsed has, to date, been quite difficult as there has…
Measurable residual disease (MRD) has become a crucial part of treatment planning and prognosis construction in many hematological diseases; however,…
Mark Levis, MD, PhD, talks about new information about gilteritinib in FLT3 mutated acute myeloid leukemia (AML) at Annual Meeting…
Mark Levis, MD, PhD, explains the impact of measurable residual disease in the clinical outcomes of patients with relapsed or…
Mark Levis, MD, PhD, explains the key factors influencing 1st line therapy in acute myeloid leukemia(AML) patients with FLT3 mutations…
Mark Levis, MD, PhD, explains the the impact of next-generation sequencing in AML at Annual Meeting 2018.
Measurable residual disease (MRD) is gaining traction not only as a prognostic indicator, but also as a tool for informing…
Fabio Guolo, MD, of the University of Genoa, Genoa, Italy, spoke to us at the 23rd Congress of the European…
The development of novel agents to treat acute myeloid leukemia (AML) is constantly revolutionizing the field. In this video, Christoph…
Measurable residual disease (MRD) is rising in popularity as a prognostic indicator in a variety of blood cancer types. We…
Esther Oliva, MD, of the Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, Italy, presented preliminary results from her Phase…
Daunorubicin is commonly used to treat acute myeloid leukemia (AML). In this video, Christoph Röllig, MD, of the University Hospital…
In this interview, Mark Levis, MD, PhD, of Sidney Kimmel Comprehensive Cancer Centre, Baltimore, MD, discusses the importantance of involving…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Guillermo Garcia-Manero, MD, of the…
Pracinostat has been shown to be an effective therapy for treating myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) in…
This is a thrilling time for the use of measurable residual disease (MRD) in acute myeloid leukemia (AML), as highlighted…
One big development in clinical trial design in acute myeloid leukemia (AML) is the inclusion of measurable residual disease (MRD)…
There are multiple methodologies for the testing of measurable residual disease (MRD), which each come with various pros and cons,…